Use of disease-modifying drugs (tocilizumab, tofacitinib, and baricitinib—a biological or synthetic target specific) in patients hospitalized with COVID-19 - Barbosa, Alexandre Naime [UNESP]; Silvinato, Antonio; Bacha, Hélio; Floriano, Idevaldo; Tanni, Suzana [UNESP]; Bernardo, Wanderley (FapUNIFESP (SciELO), 2022)